^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TPM3-NTRK1 G595R

    i
    Other names: TPM3, Tropomyosin 3, Tropomyosin Alpha-3 Chain, Tropomyosin-5, Epididymis Secretory Sperm Binding Protein Li 82p, Heat-Stable Cytoskeletal Protein 30 KDa, Alpha-Tropomyosin, Slow Skeletal, Epididymis Luminal Protein 189, Cytoskeletal Tropomyosin TM30, Tropomyosin Gamma, Gamma-Tropomyosin , Tropomyosin 3 Nu, Tropomyosin-3, OK/SW-Cl.5, HEL-S-82p, HEL-189, TM30nm, TPM3nu, TPMsk3 , Hscp30, CAPM1, CFTD, TM-5, TM30, NEM1, HTM5, TM3, TM5, TRK, NTRK1, MTC, TRK, TRKA, Neurotrophic tyrosine kinase, recept
    Entrez ID:
    4914; 7170
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    3years
    [VIRTUAL] NTRK1 fusion detection from clinical cfDNA NGS using a de novo fusion caller (AACR 2021)
    Background: NTRK rearrangements, though rare in common cancers, are clinically actionable targets with two FDA-approved drugs for pan-cancer indications, larotrectinib and entrectinib. NTRK1 fusions were detected in cfDNA at a similar prevalence to tissue NGS, demonstrating high sensitivity of plasma-based assays to detect these fusions. NTRK1 fusion partners were diverse, with the majority of partner genes observed only once across the cohort. Both clonal and subclonal NTRK1 rearrangements were detected, affirming that this biomarker can emerge as an oncogenic driver or as a mechanism of resistance.
    Clinical • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • TPM3 (Tropomyosin 3) • LMNA (Lamin A/C) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • BRAF V600 • NTRK1 fusion • EGFR L858R • KRAS G12D • KRAS G12 • EGFR positive • NTRK1 positive • EGFR fusion • NTRK positive • NTRK1 G595R • TPM3-NTRK1 G595R
    |
    Guardant360® CDx
    |
    Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)